References
- Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364(9438), 937–952 (2004).
- Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18), 1993–2000 (2009).
- Genest JJ Jr, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85(6), 2025–2033 (1992).
- Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 91(20), 9607–9611 (1994).
- Van Eck M, Singaraja RR, Ye D et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26(4), 929–934 (2006).
- Brunham LR, Singaraja RR, Duong M et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(4), 548–554 (2009).
- Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B. Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J. Mol. Med. 89(6), 555–567 (2011).
- Clee SM, Zwinderman AH, Engert JC et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 103(9), 1198–1205 (2001).
- Francis GA. The complexity of HDL. Biochim. Biophys. Acta 1801(12), 1286–1293 (2010).
- Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J. Lipid Res. 51(8), 2032–2057 (2010).
- Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841), 572–580 (2012).
- Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL – an evolving field. Nat. Clin. Pract. Endocrinol. Metab. 2(9), 504–511 (2006).
- Barter P, Gotto AM, LaRosa JC et al.; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357(13), 1301–1310 (2007).
- Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007).
- Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann. Intern. Med. 153(12), 800–808 (2010).
- Ridker PM, Genest J, Boekholdt SM et al.; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376(9738), 333–339 (2010).
- Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116(12), 3090–3100 (2006).
- Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl.), S189–S194 (2009).
- Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54, 321–341 (2003).
- Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 15(7), 265–271 (2005).
- Barter PJ. Cardioprotective effects of high-density lipoproteins: the evidence strengthens. Arterioscler. Thromb. Vasc. Biol. 25(7), 1305–1306 (2005).
- Ogorzalek Loo RR, Yam L, Loo JA, Schumaker VN. Virtual two-dimensional gel electrophoresis of high-density lipoproteins. Electrophoresis 25(14), 2384–2391 (2004).
- Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5(5), 1431–1445 (2005).
- Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 6(2), 721–730 (2006).
- Hortin GL, Shen RF, Martin BM, Remaley AT. Diverse range of small peptides associated with high-density lipoprotein. Biochem. Biophys. Res. Commun. 340(3), 909–915 (2006).
- Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117(3), 746–756 (2007).
- Ståhlman M, Davidsson P, Kanmert I et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 49(2), 481–490 (2008).
- Green PS, Vaisar T, Pennathur S et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 118(12), 1259–1267 (2008).
- Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29(6), 870–876 (2009).
- Gordon S, Durairaj A, Lu JL, Davidson WS. High-density lipoprotein proteomics: identifying new drug targets and biomarkers by understanding functionality. Curr. Cardiovasc. Risk Rep. 4(1), 1–8 (2010).
- Alwaili K, Bailey D, Awan Z, Laboissiere S, Krimbou L, Genest J. HDL Proteomics in acute coronary syndromes. BBA: Mol. Cell Biol. Lipids (2011).
- Quehenberger O, Armando AM, Brown AH et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51(11), 3299–3305 (2010).
- Sorci-Thomas MG, Owen JS, Fulp B et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J. Lipid Res. 53(9), 1890–1909 (2012).
- Nofer JR, van der Giet M, Tölle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113(4), 569–581 (2004).
- Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br. J. Pharmacol. 150(4), 470–479 (2007).
- von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr. Opin. Lipidol. 20(3), 197–205 (2009).
- Argraves KM, Gazzolo PJ, Groh EM et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 283(36), 25074–25081 (2008).
- Argraves KM, Sethi AA, Gazzolo PJ et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 10, 70 (2011).
- Liu X, Xiong SL, Yi GH. ABCA1, ABCG1, and SR-BI: transit of HDL-associated sphingosine-1-phosphate. Clin. Chim. Acta 413(3–4), 384–390 (2012).
- Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50(Suppl.), S207–S212 (2009).
- Dernick G, Obermüller S, Mangold C et al. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays. J. Lipid Res. 52(12), 2323–2331 (2011).
- Rosenson RS, Brewer HB Jr, Chapman MJ et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57(3), 392–410 (2011).
- Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60(6), 508–516 (2012).
- Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51(12), 3443–3454 (2010).
- Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96(12), 1221–1232 (2005).
- Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6(7), 455–463 (2009).
- Iatan I, Bailey D, Ruel I et al. Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. J. Lipid Res. 52(11), 2043–2055 (2011).
- Bailey D, Ruel I, Hafiane A et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. 51(4), 785–797 (2010).
- Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
- Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin. Ther. 31(2), 236–244 (2009).
- Genest J, Libby P. Lipoprotein Disorders and CAD. In: Braunwald’s Heart Disease. Braunwald E, Libby P, Zipes D, Bonow R (Eds). Saunders, New York, NY, USA (2011).
- Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735–2752 (2005).
- Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can. J. Cardiol. 25(10), 567–579 (2009).
- Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J. Lipid Res. 51(8), 2058–2073 (2010).
- Awan Z, Al Waili K, Alrasadi K, Genest J. Treatment of low high density lipoprotein cholesterol. Can J. Cardiol. 24, 27–31 (2008).
- Alrasadi K, Awan Z, Alwaili K et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am. J. Cardiol. 102(10), 1341–1347 (2008).
- Greenland P, Alpert JS, Beller GA et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 122(25), e584–e636 (2010).
- Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17(6), 631–636 (2006).
- Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298(7), 786–798 (2007).
- Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17), 2292–2300 (2003).
- Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, b92 (2009).
- Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258(2), 94–114 (2005).
- Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N. Engl. J. Med. 361(22), 2113–2122 (2009).
- Boden WE, Probstfield JL, Anderson T et al.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
- Abourbih S, Filion KB, Joseph L et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962.e1–962.e8 (2009).
- Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875–1884 (2010).
- Ginsberg HN, Elam MB, Lovato LC.; ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. NEJM 362, 1563 (2010).
- Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am. J. Cardiol. 104(1), 82–91 (2009).
- Stroes ES, Kastelein JJ, Bénardeau A et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin–angiotensin–aldosterone system in rats. Br. J. Pharmacol. 158(7), 1763–1770 (2009).
- Fayad ZA, Mani V, Woodward M et al.; dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378(9802), 1547–1559 (2011).
- Lüscher TF, Taddei S, Kaski JC et al.; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. 33(7), 857–865 (2012).
- Schwartz GG, Olsson AG, Abt M et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367(22), 2089–2099 (2012).
- Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet 370(9603), 1907–1914 (2007).
- Bloomfield D, Carlson GL, Sapre A et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157(2), 352–360.e2 (2009).
- Cannon CP, Shah S, Dansky HM et al.; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363(25), 2406–2415 (2010).
- Nicholls SJ, Brewer HB, Kastelein JJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306(19), 2099–2109 (2011).
- Degoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 8(5), 266–277 (2011).
- Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7(2), 143–155 (2008).
- Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364(2), 127–135 (2011).
- deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51(23), 2199–2211 (2008).
- Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121(1), 110–122 (2010).
- Rye KA, Barter PJ. Anti-inflammatory actions of HDL: a new insight. Arterioscler. Thromb. Vasc. Biol. 28(11), 1890–1891 (2008).
- Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50(Suppl.), S195–S200 (2009).
- Tang C, Oram JF. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta 1791(7), 563–572 (2009).
- Besler C, Heinrich K, Rohrer L et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121(7), 2693–2708 (2011).
- Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278(11), 9142–9149 (2003).
- Nicholls SJ, Dusting GJ, Cutri B et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111(12), 1543–1550 (2005).
- Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51(12), 3443–3454 (2010).
- Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275(15), 11278–11283 (2000).
- Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7(7), 853–857 (2001).
- Saddar S, Mineo C, Shaul PW. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler. Thromb. Vasc. Biol. 30(2), 144–150 (2010).
- Spieker LE, Sudano I, Hürlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105(12), 1399–1402 (2002).
- Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107(23), 2944–2948 (2003).
- Rämet ME, Rämet M, Lu Q et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41(12), 2288–2297 (2003).
- Terasaka N, Westerterp M, Koetsveld J et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler. Thromb. Vasc. Biol. 30(11), 2219–2225 (2010).
- Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-α-induced apoptosis. Biochem. Biophys. Res. Commun. 272(3), 872–876 (2000).
- Seetharam D, Mineo C, Gormley AK et al. High-density lipoprotein promotes endothelial cell migration and re-endothelialization via scavenger receptor-B type I. Circ. Res. 98(1), 63–72 (2006).
- Feng Y, Jacobs F, Van Craeyveld E et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 28(2), 278–283 (2008).
- Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, von Eckardstein A. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ. Res. 104(10), 1142–1150 (2009).
- Sumi M, Sata M, Miura S et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27(4), 813–818 (2007).
- Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26(5), 1144–1149 (2006).
- Van Linthout S, Spillmann F, Lorenz M et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 53(4), 682–687 (2009).
- Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23(7), 1283–1288 (2003).
- Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), E1–E7 (2001).
- Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353(10), 999–1007 (2005).
- Werner N, Wassmann S, Ahlers P et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res. Cardiol. 102(6), 565–571 (2007).
- Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J. Am. Coll. Cardiol. 55(15), 1553–1565 (2010).
Websites
- Lipid Metabolites and Pathway Strategy. www.lipidmaps.org
- REVEAL. (trial no: NCT01252953) http://ClinicalTrials.gov
- The ACCELERATE study. (trial no: NCT01687998) http://ClinicalTrials.gov